Neoadjuvant FOLFIRINOX

Phase II study of FOLFIRINOX for the patients with resectable or borderline resectable pancreatic adenocarcinoma

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1041220027

Enrollment

Registered

2022-06-04

Start date

2022-07-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer Pancreatic cancer, Neoadjuvant therapy

Interventions

The following regimens are administered for one course of 2 weeks Original FOLFIRINOX regimen (Age younger than 70) oxaliplatin 85mg/m2 (day1), leucovorin 200mg/m2 (day1), irinotecan 180mg/m2 (day1),

FOLFIRINOX

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pathologically diagnosed as pancreatic adenocarcinoma or adenosquamous carcinoma; diagnosed as resectable or borderline resectable (BR-PV) (cohort1) or borderline resectable (BR-A); 20-80 years or older; ECOG Performance status 0 or 1; preservation of major organ function; written informed consent

Exclusion criteria

Exclusion criteria: double cancer; severe infection; refractory ascites or pleural effusion; pregnant or lactating women, or women of childbearing potential; metastases to central nervous system; mental disorder; severe complication; patients who investigator regards as inappropriate for candidate

Design outcomes

Primary

Measure	Time frame
R0 resection rate	—

Secondary

Measure	Time frame
resection rate, pathological response, adverse event, completion rate, relative dose intensity, progression-free survival, 2-year survival, overall survival, subsequent therapy	—

Contacts

Public ContactTakeshi Terashima

Kanazawa University Hospital

tera@m-kanazawa.jp+81-76-265-2235

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026